# Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma

> **NCT02731313** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 420 (actual)

## Conditions studied

- Gastric Cancer, Gastroesophageal Junction Cancer

## Interventions

- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT02731313
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02731313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02731313, "Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02731313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*